Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Liquid biopsy may help target prostate cancer treatment

26 June 2017

By Charlotte Spicer

Appeared in BioNews 906

A new three-in-one blood test could progress personalised treatment for patients with prostate cancer.

The 'liquid biopsy' can be used to choose effective drug treatment options for men with advanced prostate cancer, as well as to monitor drug resistance, according to the study published in Cancer Discovery.

'Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib,' said Professor Johann de Bono, from the Institute of Cancer Research (ICR), London. 'From these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.'

The scientists monitored DNA released by prostate cancer cells in regular blood samples taken from 49 men with advanced prostate cancer. The men were enrolled in a clinical trial of the targeted cancer drug, olaparib.

After eight weeks of treatment, tumour DNA levels had halved in the blood of patients who responded to olaparib. In contrast, DNA levels rose by two percent on average in those who did not respond to the drug. Men who had a greater than 50 percent drop in tumour DNA after eight weeks of treatment also survived longer.

Dr Áine McCarthy at Cancer Research UK said the blood test was an important development with the 'potential to greatly improve survival for the disease'.

The researchers also investigated why some men stopped responding to olaparib. It belongs to a class of drugs called PARP-inhibitors that help kill cancer cells with mutation in genes involved in DNA repair, such as BRCA1 and BRCA2. By closely analysing the tumour DNA, they found new genetic changes that cancelled out the original mutations, causing the drug to become ineffective.

Professor Paul Workman, chief executive and president of ICR, said that the test could 'usher in a new era of precision medicine for prostate cancer' and that 'blood tests for cancer promise to be truly revolutionary'. He added that because the tests are cheap, simple to use and non-invasive they could potentially be used to monitor patients early on in treatment.

The blood test is still in early clinical trials involving small numbers of patients, but the researchers are hopeful that the test will help provide greater targeted treatment for patients with fewer side effects.

'Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well, ' Professor de Bono concluded.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

11 December 2017 - by Shaoni Bhattacharya 
UK scientists say they are closer to developing an 'early warning system' for the return of cancer in patients using a simple blood test...
21 August 2017 - by Dr Loredana Guglielmi 
US researchers have developed a new blood test to detect cancer-related DNA alterations before patients experience symptoms...

12 June 2017 - by Hannah Somers 
A highly-sensitive DNA blood test could help detect cancer years before tumours are detected...
16 January 2017 - by Annabel Slater 
Canadian scientists have identified a genetic fingerprint that indicates which prostate cancer tumours may develop into a more aggressive form of the disease after treatment...
11 July 2016 - by Antony Blackburn-Starza 
Genetic mutations on several genes including BRCA2 have been associated with prostate cancer; while in a separate study, a BRCA1 mutation has been linked to a particular form of uterine cancer...
21 December 2015 - by Lone Hørlyck 
A treatment for prostate cancer, combining radiotherapy and a new type of gene therapy, is both safe and effective, a study has found...
09 November 2015 - by Kirsty Oswald 
Researchers have identified the genetic mutations that drive resistance to the hormone therapy abiraterone in patients with advanced prostate cancer...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation